{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:20:37Z","timestamp":1787235637915,"version":"build-2736575974"},"reference-count":35,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Childhood asthma carries significant morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim\/Objectives:<\/jats:title>\n                    <jats:p>Aim of the study was to compare efficacy of 2 commonly used therapies for asthma control in children with asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a 1-year, prospective cohort study at a tertiary care children's hospital. Patients were referred by their primary care physicians (PCPs) for asthma control. All patients were on low-dose inhaled corticosteroids (ICSs) at baseline. They were either switched to medium-dose ICS (ICS group) or medium-dose ICS and long-acting beta agonist (ICS+LABA group). Results were compared over time and between both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Our cohort included 163 children (ages 2\u201318 years) with mean age of 5.62\u2009\u00b1\u20093.61 years. Mean Asthma Control Test (ACT) score at baseline was 15.9\u2009\u00b1\u20095.4. Mean ACT and percent predicted forced expiratory volume in one second improved (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 for both) in both groups. Median emergency department visits, short courses of oral steroids, and unscheduled PCP visits for acute asthma significantly decreased (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all) in both groups. Similarly, days\/month with wheezing, nighttime cough, and missed school days significantly decreased in both groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all). Patients in ICS group were more likely to fail to achieve asthma control compared to patients in ICS+LABA group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study suggests that in children with uncontrolled asthma on low-dose ICS, switching to either medium-dose ICS or medium-dose ICS+LABA resulted in better symptom control, ACT improvement, and less asthma exacerbations over time. ICS+LABA had the additional benefit of less risk of treatment failure when compared to medium-dose ICS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/ped.2020.1196","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T13:40:07Z","timestamp":1598449207000},"page":"127-135","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Two Therapies on Asthma Control in Children"],"prefix":"10.1177","volume":"33","author":[{"given":"Anas","family":"Al-Turki","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA."},{"name":"Section of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Salvator","sequence":"additional","affiliation":[{"name":"Biostatistics Resource at Nationwide Children's Hospital, Nationwide Children's Hospital, Columbus, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA."},{"name":"Biostatistics Resource at Nationwide Children's Hospital, Nationwide Children's Hospital, Columbus, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid I.","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA."},{"name":"Section of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention. Revised 2014. Available at https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/01\/2014-GINA.pdf (accessed December5 2019)."},{"key":"e_1_3_4_3_2","unstructured":"Global Initiative for Asthma. GINA Report Global Strategy for Asthma Management and Prevention. Available at https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/06\/GINA-2020-report_20_06_04-1-wms.pdf (accessed December5 2019)."},{"key":"e_1_3_4_4_2","unstructured":"Guidelines for the Diagnosis and Management of Asthma (EPR-3). NHLBI. 2007. Available at https:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/asthsumm.pdf (accessed December7 2019)."},{"key":"e_1_3_4_5_2","first-page":"CD005307","article-title":"Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children","author":"Ni Chroinin M","year":"2009","unstructured":"Ni Chroinin M, , Greenstone I, , Lasserson TJ, , Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database System Rev, 2009:CD005307.","journal-title":"Cochrane Database System Rev"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715274"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715275"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62145-9"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.6.1733"},{"key":"e_1_3_4_11_2","unstructured":"Childhood Asthma Control Test. Available at https:\/\/www.asthma.com\/additional-resources\/childhood-asthma-control-test.html (accessed October 2017)."},{"key":"e_1_3_4_12_2","first-page":"CD007949","article-title":"Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children","author":"Ni Chroinin M","year":"2009","unstructured":"Ni Chroinin M, , Lasserson TJ, , Greenstone I, , Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev, 2009:CD007949.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0193OC"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10381"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.1.9706048"},{"key":"e_1_3_4_16_2","first-page":"CD005533","article-title":"Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma","author":"Ducharme FM","year":"2010","unstructured":"Ducharme FM, , Ni Chroinin M, , Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev, 2010:CD005533.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_17_2","first-page":"CD002314","article-title":"Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and\/or chronic asthma in adults and children","volume":"2012","author":"Chauhan BF","year":"2012","unstructured":"Chauhan BF, , Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and\/or chronic asthma in adults and children. Cochrane Database Syst Rev, 2012; 2012:CD002314.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_18_2","first-page":"CD003534","article-title":"Fluticasone at different doses for chronic asthma in adults and children","volume":"2008","author":"Adams NP","year":"2008","unstructured":"Adams NP, , Bestall JC, , Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev, 2008; 2008:CD003534.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_19_2","first-page":"CD003137","article-title":"Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma","author":"Chauhan BF","year":"2014","unstructured":"Chauhan BF, , Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev, 2014:CD003137.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.1.75"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260801"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.149.3.8118625"},{"key":"e_1_3_4_23_2","first-page":"CD006363","article-title":"Regular treatment with salmeterol for chronic asthma: serious adverse events","volume":"3","author":"Cates CJ","year":"2008","unstructured":"Cates CJ, , Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev, 2008; 3:CD006363.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6884.1034"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1.15"},{"key":"e_1_3_4_26_2","unstructured":"Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 2008. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4398b1-01-FDA.pdf (accessed October2016)."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.116608"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511049"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/753083"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.5.8630590"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711133372001"},{"key":"e_1_3_4_32_2","first-page":"423","article-title":"Salmeterol xinafoate in children on high dose inhaled steroids","volume":"75","author":"Russell G","year":"1995","unstructured":"Russell G, , Williams DA, , Weller P, , Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol, 1995; 75:423\u2013428.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10404"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0193OC"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001278"},{"key":"e_1_3_4_36_2","first-page":"CD007949","article-title":"Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children","author":"Chauhan BF","year":"2015","unstructured":"Chauhan BF, , Chartrand C, , Ni Chroinin M, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev, 2015; CD007949.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ped.2020.1196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2020.1196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2020.1196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:14:50Z","timestamp":1777677290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/ped.2020.1196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1089\/ped.2020.1196"],"URL":"https:\/\/doi.org\/10.1089\/ped.2020.1196","relation":{},"ISSN":["2151-321X","2151-3228"],"issn-type":[{"value":"2151-321X","type":"print"},{"value":"2151-3228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}